Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Effectiveness Uncovered: A Survey of \Smoothing out Your Errands\ Efficiency Application - 2Two die and thousands homeless after flooding hits Russia's Dagestan
- 35 Christmas movies to stream for less with this Paramount+ Black Friday deal
- 4Vote In favor of Your Favored Language Learning Applications
- 5Russian drone slams into block of flats in deadly wave of strikes across Kyiv
- Former IRGC child executioner tells ‘Post’ how he became devout Christian dissident
- 5 Advancement Developments in Biotechnology
- Esteem Stuffed Gaming Workstations to Consider
- Do-It-Yourself Home Style on a Careful spending plan: Imaginative Thoughts and Tasks
- A photographer's journey to capture a blood moon rising over the South China Sea. 'It was an incredible moment'
- If everyone on Earth sat in the ocean at once, how much would sea level rise?
- What’s the shadowy organisation taking Gaza Palestinians to South Africa?
- Popular Japanese Hotel Chain Now Lets You Show Up With Just Your Passport
- Fetterman says he's back home after a fall put the Pennsylvania senator in the hospital
